VERTEX PHARMACEUTICALS INC / MA Payments to Acquire Available-for-sale Securities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Payments to Acquire Available-for-sale Securities of $431.92 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $38.65M, a 84.43% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $100.93M.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $53.99M, a 63.16% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $129.39M, a 47.28% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for fiscal 2018 was $431.92M, a 18.90% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for fiscal 2017 was $532.58M, a 13.63% decline from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for fiscal 2016 was $616.63M, a 2.59% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire available-for-sale securities for fiscal 2015 was $633.04M, a 55.55% decline from fiscal 2014.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $431.92M 10-K · filed 2019-02-13 | |||
| 2018-03-31 | $38.65M 10-Q · filed 2018-04-27 | $139.58M derived: sum of 2 quarters · filed 2020-02-13 | $193.57M derived: sum of 3 quarters · filed 2020-02-13 | $322.96M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $100.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $154.91M derived: sum of 2 quarters · filed 2020-02-13 | $284.31M derived: sum of 3 quarters · filed 2020-02-13 | $532.58M 10-K · filed 2020-02-13 |
| 2017-09-30 | $53.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $183.38M derived: sum of 2 quarters · filed 2018-07-26 | $431.65M 10-Q · filed 2017-10-30 | $431.65M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $129.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $377.67M 10-Q · filed 2018-07-26 | $377.67M derived: sum of 3 quarters · filed 2019-02-13 | $524.22M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $248.27M 10-Q · filed 2018-04-27 | $248.27M derived: sum of 2 quarters · filed 2019-02-13 | $394.82M derived: sum of 3 quarters · filed 2019-02-13 | $640.27M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $146.55M derived: sum of 2 quarters · filed 2019-02-13 | $392.00M derived: sum of 3 quarters · filed 2019-02-13 | $616.63M 10-K · filed 2019-02-13 |
| 2016-09-30 | $146.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $392.00M derived: sum of 2 quarters · filed 2017-10-30 | $616.63M 10-Q · filed 2017-10-30 | $957.53M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $245.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $470.08M 10-Q · filed 2017-07-28 | $810.98M derived: sum of 3 quarters · filed 2018-02-15 | $977.46M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $224.62M 10-Q · filed 2017-04-28 | $565.53M derived: sum of 2 quarters · filed 2018-02-15 | $732.01M derived: sum of 3 quarters · filed 2018-02-15 | $732.01M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $340.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $507.39M derived: sum of 2 quarters · filed 2018-02-15 | $507.39M derived: sum of 3 quarters · filed 2018-02-15 | $633.04M 10-K · filed 2018-02-15 |
| 2015-09-30 | $166.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $166.48M derived: sum of 2 quarters · filed 2016-10-31 | $292.13M 10-Q · filed 2016-10-31 | $649.53M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $125.66M 10-Q · filed 2016-08-01 | $483.06M derived: sum of 3 quarters · filed 2017-02-23 | $845.85M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $125.66M 10-Q · filed 2016-05-03 | $483.06M derived: sum of 2 quarters · filed 2017-02-23 | $845.85M derived: sum of 3 quarters · filed 2017-02-23 | $1.17B derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $357.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $720.20M derived: sum of 2 quarters · filed 2017-02-23 | $1.04B derived: sum of 3 quarters · filed 2017-02-23 | $1.42B 10-K · filed 2017-02-23 |
| 2014-09-30 | $362.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $685.82M derived: sum of 2 quarters · filed 2015-10-30 | $1.07B 10-Q · filed 2015-10-30 | $1.63B derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $323.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $703.98M 10-Q · filed 2015-08-04 | $1.27B derived: sum of 3 quarters · filed 2016-02-16 | $2.22B derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $380.95M 10-Q · filed 2015-05-04 | $943.35M derived: sum of 2 quarters · filed 2016-02-16 | $1.89B derived: sum of 3 quarters · filed 2016-02-16 | $2.33B derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $562.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $1.51B derived: sum of 2 quarters · filed 2016-02-16 | $1.95B derived: sum of 3 quarters · filed 2016-02-16 | $2.41B 10-K · filed 2016-02-16 |
| 2013-09-30 | $951.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.39B derived: sum of 2 quarters · filed 2014-11-06 | $1.85B 10-Q · filed 2014-11-06 | $2.25B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $439.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $898.71M 10-Q · filed 2014-07-31 | $1.30B derived: sum of 3 quarters · filed 2015-02-13 | $1.83B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $458.97M 10-Q · filed 2014-05-05 | $855.76M derived: sum of 2 quarters · filed 2015-02-13 | $1.39B derived: sum of 3 quarters · filed 2015-02-13 | $1.76B derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $396.79M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $928.23M derived: sum of 2 quarters · filed 2015-02-13 | $1.30B derived: sum of 3 quarters · filed 2015-02-13 | $1.71B 10-K · filed 2015-02-13 |
| 2012-09-30 | $531.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $905.87M derived: sum of 2 quarters · filed 2013-11-07 | $1.31B 10-Q · filed 2013-11-07 | $1.78B derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $374.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $777.60M 10-Q · filed 2013-08-02 | $1.25B derived: sum of 3 quarters · filed 2014-02-11 | $1.36B derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $403.18M 10-Q · filed 2013-05-08 | $873.63M derived: sum of 2 quarters · filed 2014-02-11 | $989.62M derived: sum of 3 quarters · filed 2014-02-11 | $999.73M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $470.46M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $586.44M derived: sum of 2 quarters · filed 2014-02-11 | $596.55M derived: sum of 3 quarters · filed 2014-02-11 | $721.54M 10-K · filed 2014-02-11 |
| 2011-09-30 | $115.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $126.09M derived: sum of 2 quarters · filed 2012-11-06 | $251.09M 10-Q · filed 2012-11-06 | $711.28M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $10.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $135.11M 10-Q · filed 2012-08-08 | $595.30M derived: sum of 3 quarters · filed 2013-03-01 | $1.05B derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $125.00M 10-Q · filed 2012-05-10 | $585.18M derived: sum of 2 quarters · filed 2013-03-01 | $1.04B derived: sum of 3 quarters · filed 2013-03-01 | $1.32B derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $460.19M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $913.47M derived: sum of 2 quarters · filed 2013-03-01 | $1.19B derived: sum of 3 quarters · filed 2013-03-01 | $1.23B 10-K · filed 2013-03-01 |
| 2010-09-30 | $453.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $732.51M derived: sum of 2 quarters · filed 2011-11-03 | $774.53M 10-Q · filed 2011-11-03 | $1.59B derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $279.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $321.25M 10-Q · filed 2011-08-09 | $1.13B derived: sum of 3 quarters · filed 2012-02-22 | $1.26B derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $42.02M 10-Q · filed 2011-05-06 | $853.96M derived: sum of 2 quarters · filed 2012-02-22 | $978.01M derived: sum of 3 quarters · filed 2012-02-22 | |
| 2009-12-31 | $811.93M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $935.99M derived: sum of 2 quarters · filed 2012-02-22 | $1.19B 10-K · filed 2012-02-22 | |
| 2009-09-30 | $124.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $374.77M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $250.72M 10-Q · filed 2010-08-03 | |||
| 2008-12-31 | $755.42M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |